Benjamin L Prosser
Overview
Explore the profile of Benjamin L Prosser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
2190
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dual Translational Control in Cardiomyocytes by Heterogeneous mTORC1 and Hypertrophic ERK Activation
Uchida K, Scarborough E, Prosser B
bioRxiv
. 2025 Feb;
PMID: 39990478
Background: Cardiac hypertrophy allows post-mitotic cardiomyocytes to meet increased hemodynamic demands but can predispose the heart to adverse clinical outcomes. Despite its central role in cardiac adaptation, the translational control...
2.
Latchman N, Stevens T, Bedi K, Prosser B, Margulies K, Elrod J
bioRxiv
. 2025 Feb;
PMID: 39975328
Background: Cardiomyocyte structural remodeling is reported as a causal contributor to heart failure (HF) development and progression. Growing evidence highlights the role of organelle apposition in cardiomyocyte function and homeostasis....
3.
Pietsch N, Chen C, Kupsch S, Bacmeister L, Geertz B, Herrera-Rivero M, et al.
Circ Res
. 2024 Sep;
135(9):910-932.
PMID: 39279670
Background: Hypertrophic cardiomyopathy (HCM) is the most common cardiac genetic disorder caused by sarcomeric gene variants and associated with left ventricular hypertrophy and diastolic dysfunction. The role of the microtubule...
4.
Felix A, Wilson T, Randell R, Marotta N, Uchida K, Boland M, et al.
bioRxiv
. 2024 Sep;
PMID: 39229131
Heterozygous variants in and lead to distinct neurodevelopmental disorders caused by haploinsufficient levels of post-synaptic SYNGAP1 and pre-synaptic STXBP1, which are critical for normal synaptic function. While several gene-targeted therapeutic...
5.
6.
Eaton D, Lee B, Caporizzo M, Iyengar A, Chen C, Uchida K, et al.
Sci Transl Med
. 2024 Jul;
16(756):eadm8842.
PMID: 39018366
Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome associated with increased myocardial stiffness and cardiac filling abnormalities. Prior studies implicated increased α-tubulin detyrosination, which is catalyzed by...
7.
Liutkute A, Prosser B, Voigt N
Cardiovasc Res
. 2024 Apr;
120(7):671-672.
PMID: 38637305
No abstract available.
8.
Marotta N, Boland M, Prosser B
Curr Probl Pediatr Adolesc Health Care
. 2024 Mar;
54(8):101576.
PMID: 38472035
Gene-targeted therapies for genetic neurodevelopmental disorders (NDDs) are becoming a reality. The Center for Epilepsy and Neurodevelopmental Disorders (ENDD) is currently focused on the development of therapeutics for STXBP1 and...
9.
Yan G, Han Z, Kwon Y, Jousma J, Nukala S, Prosser B, et al.
Circ Res
. 2024 Feb;
134(5):482-501.
PMID: 38323474
Background: Mitochondrial dysfunction is a primary driver of cardiac contractile failure; yet, the cross talk between mitochondrial energetics and signaling regulation remains obscure. Ponatinib, a tyrosine kinase inhibitor used to...
10.
McAfee Q, Caporizzo M, Uchida K, Bedi Jr K, Margulies K, Arany Z, et al.
J Clin Invest
. 2023 Nov;
134(2).
PMID: 37943622
No abstract available.